Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)

被引：1
|
作者：
Duvic, M.
Vanaclocha, F.
Bernengo, M. G.
Okada, C.
Breneman, D.
Zinzani, P. L.
Zhang, L.
Bopp, K.
Laird, G.
Hirawat, S.
Prince, M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Turin, Turin, Italy
[3] Portland VA Med Ctr, Portland, OR USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Ist Ematol Oncol Med, Bologna, Italy
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8555
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A PHASE IB DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    San Miguel, J.
    Sezer, O.
    Siegel, D.
    Guenther, A.
    Blade, J.
    Prosser, I.
    Hazell, K.
    Bengoudifa, R.
    Klebsattel, M.
    Bourquelot, P.
    Cavo, M.
    Goebeler, M.
    Niederweiser, D.
    Milder, M.
    Boccadoro, M.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 155
  • [42] Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma
    Prince, H. M.
    George, D.
    Patnaik, A.
    Mita, M.
    Dugan, M.
    Butterfoss, D.
    Masson, E.
    Culver, K. W.
    Burris, H. A., III
    Beck, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease
    Perez, Lia
    Field, Teresa
    Riches, Marcie L.
    Fernandez, Hugo F.
    Locke, Frederick L.
    Betts, Brian C.
    Pidala, Joseph
    Elmer, Erika
    Beato, Francisca
    Lienlaf, Maritza
    Horna, Pedro
    Villagra, Alejandro
    Anasetti, Claudio
    BLOOD, 2014, 124 (21)
  • [44] Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma
    Younes, Anas
    Copeland, Amanda
    Fanale, Michelle A.
    Hagemeister, Fredrick
    Fayad, Luis
    Pro, Barbara
    Faria, Silvana C.
    Ji, Yuan
    Medeiros, L. Jeffrey
    Berry, Donald A.
    Buglio, Daniela
    BLOOD, 2010, 116 (21) : 1617 - 1617
  • [45] Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma
    Kim, Miryoung
    Thompson, Lisa A.
    Wenger, Sarah D.
    O'Bryant, Cindy L.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (10) : 1340 - 1348
  • [46] A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Giles, Francis
    Fischer, Thomas
    Cortes, Jorge
    Garcia-Manero, Guillermo
    Beck, Joachim
    Ravandi, Farhad
    Masson, Eric
    Rae, Patricia
    Laird, Glen
    Sharma, Sunil
    Kantarjian, Hagop
    Dugan, Margaret
    Albitar, Maher
    Bhalla, Kapil
    CLINICAL CANCER RESEARCH, 2006, 12 (15) : 4628 - 4635
  • [47] A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease
    Perez, Lia
    Fernandez, Hugo F.
    Tomblyn, Marcie
    Locke, Frederick L.
    Field, Teresa
    Pidala, Joseph
    Elmer, Erika
    Beato, Francisca
    Villagra, Alejandro
    Anasetti, Claudio
    BLOOD, 2013, 122 (21)
  • [48] Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary A.
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2011, 118 (21) : 755 - 755
  • [49] Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
    Richardson, Paul G.
    Alsina, Melissa
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael
    Mukhopadhyay, Sutapa
    Snodgrass, Susan
    Schlossman, Robert
    BLOOD, 2011, 118 (21) : 370 - 371
  • [50] A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).
    Berenson, James R.
    Yellin, Ori
    Boccia, Ralph V.
    Nassir, Youram
    Rothstein, Shellie
    Swift, Regina A.
    BLOOD, 2009, 114 (22) : 736 - 736
12345